Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase NA 2Phase 4 2Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 2Genitourinary 1Gastrointestinal 1

Conditions

Breast Neoplasms 49Neoplasms 36Prostatic Neoplasms 25Carcinoma, Non-Small-Cell Lung 25Polycystic Ovary Syndrome 16Pain 15Keratosis, Actinic 14Leukemia 12Colorectal Neoplasms 11Uterine Cervical Neoplasms 10Pancreatic Neoplasms 10Lung Neoplasms 10Leiomyoma 10Carcinoma, Hepatocellular 10Ovarian Neoplasms 9Neoplasm Metastasis 9Lymphoma, Follicular 9Carcinoma, Renal Cell 9Brain Neoplasms 9Neuroendocrine Tumors 8Arthritis, Rheumatoid 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Melanoma 7Kidney Neoplasms 7Head and Neck Neoplasms 7Colonic Neoplasms 7Cancer Pain 7Multiple Myeloma 6Lymphoma 6Liver Neoplasms 6

Interventions

Dalteparin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Has results × Venous Thrombosis × Clear all
NCT03006562 2020-08-05

PREVENTER

Johns Hopkins University

Phase 4 Terminated
501 enrolled 13 charts
Classical hematologyGenitourinary

Prostatic Neoplasms, Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

NCT00966277 2016-12-12

Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients

M.D. Anderson Cancer Center

Phase 4 Completed
87 enrolled 9 charts
Classical hematologyGastrointestinal

Pancreatic Neoplasms, Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡